Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Paranasal sinus and nasal cavity cancer
Trial Status:  Active
Results 1-25 of 240 for your search:
Start Over
p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-001, NCT00894153
Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: METC 11-2-007, NCT01317589
Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CD2 AIRO, NCT01707641
The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HKM refeeding, NCT01845922
Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MITOCET, 2013-001296-20, NCT02015650
THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: NAC+Cisplatin2014, NCT02241876
Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO201007, NCT01598402
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: R05-0076, NCT00207298
Tranexamic Acid and Head and Neck Surgery Patients
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: TCVGH-957001A, 941117/C05186, NCT00308880
Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: T301, INTROGEN-T301, NCT00041613
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: T302, INTROGEN-T302, UCLA-0312111-01, NCT00041626
Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: TADDOR, CSET 1388, NCT00935675
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EUDRACT NUMBER 2009-013402-14, NCT00999700
Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer
Phase: Phase III
Type: Supportive care
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2010-0547 MDA, MDA-04-01, CDR0000674208, 2010-0547, NCI-2011-02073, U10, NCT01141231
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
Phase: Phase III
Type: Biomarker/Laboratory analysis
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000715505, ECOG-E5397T3, E5397T3, NCT01466244
Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RT2011-04, NCT01955239
Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2008-002159-25, 2008/1388, NCT02246244
Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis
Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: UBrasilia, NCT02251392
Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 55
Sponsor: Other
Protocol IDs: pro00046671, NCT02268344
Oral Glutamine and Mucositis of Head and Neck Cancer Patients Undergoing Radiation
Phase: Phase III
Type: Supportive care
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: TCVGH-1047004C, NCT02282839
Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: TianjinCIH, NCT02303197
Efficacy of EPA-enriched Supplement in Malnourished Head and Neck Cancer Patients Undergone Surgery
Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 15 to 90
Sponsor: Other
Protocol IDs: REC 57-073-13-1, NCT02321631
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: L00070 IN 309 F0, NCT02347332
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-048, 2014-003698-41, NCT02358031
Start Over